To cite: Boukhris I, Azzabi S, Cherif E, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2015-211919 DESCRIPTION A 24-year-old man presented with a 1-year history of increasing swelling in the upper lip with a painful ulcer on the external oral mucosa. On physical examination, the upper lip showed swelling cheilitis, crusting and fissuring lesions. On the ...

BACKGROUND The treatment of Leishmaniasis caused by Leishmania (Viannia) guyanensis is based on a weak strength of evidence from very few clinical trials and some case series reports. Current treatment guidelines recommend pentamidine isethionate or meglumine antimoniate (Glucantime) as the first-line choices. Both are parenteral drugs with a low therapeutic indexes leading to a high risk of un...

BACKGROUND Coordination compounds of pentavalent antimony have been, and remain, the first-line drugs in leishmaniasis treatment for >70 years. Molecular forms of Sb (V) complexes are commercialized as sodium stibogluconate (Pentostam®) and meglumine antimoniate (MA) (Glucantime®). Ever-increasing drug resistance in the parasites limits the use of antimonials, due to the low drug concentrations...

FUNDAMENTALS American tegumentary leishmaniasis (ATL) treatment remains a challenge, since most available drugs are injectable and only a small number of comparative, randomized clinical trials have been performed to support their use. Moreover, treatment outcome may depend on the causative species of Leishmania. OBJECTIVES To evaluate and compare the efficacy and tolerability of meglumine an...

BACKGROUND Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to clinics to receive MA. We performed a cost-effectiveness analysis comparing miltefosine by cDOT versu...

BACKGROUND & OBJECTIVES Leishmaniasis is a major public health problem, and the alarming spread of parasite resistance underlines the importance of discovering new therapeutic products. The present study aims to investigate the in vitro antileishmanial activity and cytotoxicity of the ethanolic extract of Berberis vulgaris fruits and chloroform extract of Nigella sativa seeds against Leishmania...

background: glucantime ® is the first- line drug for the treatment of all forms of leishmaniasis. unfortunately, the prevalence of parasites becoming resistant to glucantime ® is increasing in several parts of the world including iran. as protein is the most important target for drugs in response to a variety of signals including drugs so, it seems expression protein patterns in sensitive and r...

To date, there are no vaccines against Leishmania, and chemotherapy remains the mainstay for the control of leishmaniasis. The drugs of choice used for leishmaniasis therapy are significantly toxic, expensive and with a growing frequency of refractory infections. Because of these limitations, a combination therapy is the better hope. This work demonstrates that the essential oil from Chenopodiu...